On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory ...

The newly FDA-approved linvoseltamab (Lynozyfic; Regeneron) may improve access to multiple myeloma treatment by offering an off-the-shelf, outpatient option that can be administered in community ...

--Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Sundar Jagannath, MD, to its scientific advisory board.

If you were to meet Dr. Sundar Jagannath in a crowded room (not that we have those anymore in the COVID-19 era), you would not assume that not only is he one of the greatest myeloma docs of all time, ...

Dr. Sundar Jagannath, a multiple myeloma expert at the Icahn School of Medicine at Mount Sinai, in New York, said he can now tell a 75-year-old, newly diagnosed patient they are unlikely to die of ...

Patients and Methods Three cohorts were enrolled and treated with elotuzumab (5.0, 10, or 20 mg/kg intravenously) on days 1, 8, 15, and 22 of a 28-day cycle in the first two cycles, and days 1 and 15 ...

News provided by Caribou Biosciences, Inc. Nov 06, 2023, 8:00 AM ET -- Dr. Jagannath is a renowned expert in the research and treatment of multiple myeloma -- ...

Dr. Jagannath is a distinguished oncologist who is renowned for his groundbreaking contributions to the field of multiple myeloma,” said Syed Rizvi, MD, Caribou’s chief medical officer. “Dr.